Statements (63)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:virus
|
gptkbp:associated_with |
chronic liver disease
extrahepatic manifestations increased liver cancer risk |
gptkbp:cause |
Hepatitis B infection
|
gptkbp:community_health |
in many countries
|
gptkbp:condition |
gptkb:hepatocellular_carcinoma
liver failure hepatitis D virus co-infection |
gptkbp:data_usage |
higher in healthcare settings
|
gptkbp:diagnosis |
blood test
|
gptkbp:discovered_by |
gptkb:1967
|
gptkbp:diseases |
can lead to liver cancer
can lead to liver cirrhosis may be asymptomatic can resolve spontaneously |
gptkbp:duration |
may last for years
|
gptkbp:epidemiology |
endemic in Asia and Africa
|
gptkbp:family |
gptkb:Hepadnaviridae
|
https://www.w3.org/2000/01/rdf-schema#label |
Hepatitis B virus
|
gptkbp:incubation_period |
30 to 180 days
|
gptkbp:is_vulnerable_to |
gptkb:HBV_vaccine
|
gptkbp:liver_biopsy |
used for assessing liver damage
|
gptkbp:liver_transplant |
may be necessary in severe cases
|
gptkbp:prevalence |
approximately 257 million people infected
|
gptkbp:prevention |
vaccination
safe sex practices avoid sharing needles |
gptkbp:recommendation |
universal vaccination of infants
|
gptkbp:research_focus |
immune response
vaccine development pathogenesis antiviral resistance |
gptkbp:risk_factor |
travel to endemic areas
multiple sexual partners unprotected sex healthcare exposure injection drug use |
gptkbp:risk_of_transmission |
higher in chronic carriers
|
gptkbp:seed_dispersal |
partially double-stranded DNA
|
gptkbp:serological_marker |
HBs Ag
anti-HBc anti-HBs |
gptkbp:symptoms |
fatigue
nausea abdominal pain jaundice loss of appetite |
gptkbp:transmission |
gptkb:blood
sexual contact mother to child |
gptkbp:treatment |
antiviral medications
interferon therapy suppress viral replication prevent liver damage nucleos(t)ide analogs reduce risk of liver cancer |
gptkbp:type_of |
adr
adw ayw |
gptkbp:bfsParent |
gptkb:Hepadnaviridae
gptkb:Hepatitis_B |
gptkbp:bfsLayer |
6
|